Cargando…

Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia

BACKGROUND: Aripiprazole has been reported to worsen psychotic symptoms when switching from other antipsychotics, possibly due to dopamine supersensitivity psychosis. OBJECTIVE: This study aimed to explore the predictors and possible underlying mechanisms of aripiprazole-related psychotic exacerbati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Chia-Hao, Chan, Hung-Yu, Hsieh, Ming H., Liu, Chen-Chung, Liu, Chih-Min, Hwu, Hai-Gwo, Kuo, Ching-Hua, Chen, Wei J., Hwang, Tzung-Jeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801645/ https://www.ncbi.nlm.nih.gov/pubmed/35111295 http://dx.doi.org/10.1177/20451253211064396

Ejemplares similares

PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
por: Jen, Ya-Wen, et al.
Publicado: (2020)

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
por: Yin, John, et al.
Publicado: (2017)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis
por: Hsieh, Ming H., et al.
Publicado: (2019)

Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose
por: Liu, Chen-Chung, et al.
Publicado: (2023)

S122. TEN-YEAR FOLLOW-UP AFTER FIRST EPISODE PSYCHOSIS: FOCUSED ON LOW DOSE ANTIPSYCHOTIC MAINTENANCE AND FUNCTIONING
por: Liu, Chen-Chung, et al.
Publicado: (2020)

Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis
por: Liu, Chen-Chung, et al.
Publicado: (2021)

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report
por: Tadokoro, Shigenori, et al.
Publicado: (2017)

Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
por: Yen, Ko, et al.
Publicado: (2022)

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
por: Kanahara, Nobuhisa, et al.
Publicado: (2021)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia
por: Yu, Rongjun, et al.
Publicado: (2013)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity
por: Kruyer, Anna, et al.
Publicado: (2021)

Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole
por: Osuna-Luque, Jaime, et al.
Publicado: (2018)

Hemispheric lateralization of semantic processing before and after aripiprazole treatment in first-episode psychosis or ultra-high risk state
por: Hwang, Tzung-Jeng, et al.
Publicado: (2022)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests
por: Lin, Yi-Ting, et al.
Publicado: (2012)

A Diagnostic Model Incorporating P50 Sensory Gating and Neuropsychological Tests for Schizophrenia
por: Shan, Jia-Chi, et al.
Publicado: (2013)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
por: de Bartolomeis, Andrea, et al.
Publicado: (2015)

Limonene Inhibits Methamphetamine-Induced Sensitizations via the Regulation of Dopamine Receptor Supersensitivity
por: Gu, Sun Mi, et al.
Publicado: (2019)

Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
por: Lee, Jung-Sun, et al.
Publicado: (2010)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Supersensitive phospholipid sensing
por: LeBrasseur, Nicole
Publicado: (2005)

Supersensitiveness to Serum-Injections
Publicado: (1909)

T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA
por: Hwang, Tzung-Jeng, et al.
Publicado: (2018)

Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum?
por: Tibrewal, Prashant, et al.
Publicado: (2023)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis
por: Kobayashi, Remiko, et al.
Publicado: (2020)

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases
por: Kanahara, Nobuhisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oma9tpjlgpj7ma1o8530gs3d9t